title: Time course of change in calcium x phosphorus product after percutaneous ethanol injection therapy.
abstract: BACKGROUND
  Percutaneous ethanol injection therapy (PEIT) effectively suppresses PTH secretion, but the change in the serum calcium and phosphorus product (Ca x P) after PEIT has not been fully evaluated.
  
  
  METHODS
  Twenty-seven haemodialysis patients with severe secondary hyperparathyroidism (2HPT) were divided into two groups according to their intact PTH (i-PTH) concentrations 6 months after PEIT: (i). effective (E) group, i-PTH concentration <360 pg/ml; and (ii). non-effective (N) group i-PTH > or = 360 pg/ml. The changes in serum calcium and phosphorus concentrations and the Ca x P were recorded for the following 2 years under post-PEIT medical treatment with oral calcitriol or intravenous 22-oxacalcitriol (OCT).
  
  
  RESULTS
  In the E group, the i-PTH concentrations decreased to <300 pg/ml 1 year after PEIT (801+/-302 to 280+/-134 pg/ml), then increased to 435+/-201 pg/ml at 2 years. Serum calcium concentration did not show any significant change except for a transient reduction at 1 month after PEIT. The Ca x P decreased for 1 year (from 66.3+/-15.3 to 56.2+/-10.3 mg(2)/dl(2); P<0.05), in agreement with the course of phosphorus concentration, and continued to be <60 mg(2)/dl(2) up to 2 years after PEIT. The Ca x P tended to decrease more with OCT than oral calcitriol. In the N group, calcium and Ca x P increased significantly at 6 months after PEIT and remained at a high value.
  
  
  CONCLUSIONS
  Treatment with PEIT suppresses serum PTH concentration as well as Ca x P in the long term.
authors.affiliation: Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan. f.koiwa@sa2.so-net.ne.jp
authors.forename: Fumihiko
authors.initials: F
authors.lastname: Koiwa
authors.forename: Takeshi
authors.initials: T
authors.lastname: Hasegawa
authors.forename: Ichiro
authors.initials: I
authors.lastname: Kojima
authors.forename: Terukuni
authors.initials: T
authors.lastname: Ideura
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D002117:Calcitriol / Q000008:administration & dosage / Q000031:analogs & derivatives; D002118:Calcium / Q000097:blood*; D000431:Ethanol / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy* / Q000209:etiology*; D015552:Injections, Intralesional; D007275:Injections, Intravenous; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009994:Osmolar Concentration; D010758:Phosphorus / Q000097:blood*; D006435:Renal Dialysis; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D010758:Phosphorus; D000431:Ethanol; D002117:Calcitriol; C051883:maxacalcitol; D002118:Calcium